Status:
COMPLETED
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
GLP-1 is an incretin hormone which is discharged from the intestines after food intake. The hormone is known for its powerful insulinotropic and trophic effects on the beta cells in the pancreas and i...
Eligibility Criteria
Inclusion
- Caucasians over 18
- Emitted for non-acute coronary arteriography (CAG) in Gentofte hospital
- BMI 23-35 kg/m2
- Normal hemoglobin
- Who gives informed consent
- Those with type 2 diabetes: HbA1c 6-10%
- Those without type 2 diabetes: Normal oral glucose tolerance test (OGTT) according to WHO criteria
Exclusion
- Liver disease (ALAT \> 2x normal)
- Diabetic nefropati (Creatinine \> 130 µM or albuminuria)
- Treatment with medicine that cannot be paused 12 hours before intervention
- Pregnancy or breastfeeding
- Insulin- or glitazone treatment
- Healthy controls: close family history with diabetes
- Unstable angina pectoris
- Non-STEMI
- Atrial fibrillation
- Valvular disease
- LVEF \< 50%
- Severe systemic disease
- Type 1 diabetes
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00923962
Start Date
June 1 2009
End Date
January 1 2012
Last Update
September 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Gentofte, Department of Cardiology
Gentofte Municipality, Denmark, 2900